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1. Abstract 1 
The spatiotemporally controlled delivery of the pro-osteogenic factor rhBMP-2 would 2 
overcome most of the severe secondary effects linked to the products delivering this protein 3 
for bone regeneration. With this in mind, the aim of the present work was to develop a 4 
controlled rhBMP-2 release system using collagen-hydroxyapatite (CHA) scaffolds, which had 5 
been previously optimized for bone regeneration, as delivery platforms to produce a device 6 
with enhanced capacity for bone repair.  Spray-drying and emulsion techniques were used to 7 
encapsulate bioactive rhBMP-2 in alginate and PLGA microparticles, with a high 8 
encapsulation efficiency. After incorporation of these microparticles into the scaffolds, 9 
rhBMP-2 was delivered in a sustained fashion for up to 28 days. When tested in vitro with 10 
osteoblasts, these eluting materials showed an enhanced pro-osteogenic effect. From these 11 
results, an optimal rhBMP-2 eluting scaffold composition was selected and implanted in 12 
critical-sized calvarial defects in a rat model, where it demonstrated excellent healing capacity 13 
in vivo. These platforms have an immense potential in the field of tissue regeneration; by tuning 14 
the specific therapeutic molecule to the tissue of interest and by utilising different collagen-15 
based scaffolds, similar systems can be developed for enhancing the healing of a diverse range 16 
of tissues and organs. 17 
 18 
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3. Introduction 1 
Bone morphogenetic proteins (BMPs) are the most important growth factors (GF) in bone 2 
formation and healing. It is well known that they enable skeletal tissue formation during 3 
embryogenesis and throughout adulthood as well as bone growth and repair[1]. To date, more 4 
than 30 BMPs have been reported and among them BMP-2, -4, and -7 are each known to 5 
stimulate new bone formation at ectopic sites in vivo in critical sized defects[2, 3]. In particular, 6 
BMP-2 is known as a primary GF in bone formation involved in the commitment of multipotent 7 
stem cells to the osteogenic lineage. Additionally, recombinant human BMPs (rhBMPs) have 8 
been isolated by purification and cloning and are widely available for regenerative 9 
applications[4]. 10 
BMPs were first described in 1965 but it was not until 1998 that Johnson et al. found the 11 
possibility of their clinical application by purifying endogenous bone and utilizing it in human 12 
patients to heal long bone non-unions and segmental defects[5, 6]. rhBMP-2 was approved by 13 
the FDA in 2002 to be used in spinal fusion. Based on this, Medtronic’s INFUSE®, a collagen 14 
sponge soaked with rhBMP-2, was commercialized the same year. This product is the market 15 
leader in the bone graft field with 44 % of the $1.9 billion market; however, it has been 16 
associated with numerous complications such as heterotopic ossification, osteolysis, increased 17 
neurological deficits, retrograde ejaculation, or cancer. These serious side effects have been 18 
linked to the uncontrolled and offsite release of rhBMP-2[7, 8].  Thus while problems exist, 19 
due to the outstanding pro-osteogenic effect of this growth factor, a major focus of research is 20 
on developing biomaterials for the spatiotemporally controlled delivery of rhBMP-2 to the 21 
defect site. In this sense, a myriad of polymeric matrices, ceramic scaffolds or hydrogel based 22 
materials have been tested in the last decade, showing very promising results[9-13]. 23 
We have recently developed a porous collagen-hydroxyapatite (CHA) scaffold with immense 24 
potential for bone repair as it is biodegradable, biocompatible, osteoconductive and 25 
osteoinductive[14-16]. The localized and sustained delivery of rhBMP-2 to the defect site once 26 
implanted would further enhance the regenerative capacity of this material which may be 27 
applied to an expanded range of bone regeneration applications. One way to incorporate 28 
rhBMP-2 into these CHA scaffolds would be to pre-load the protein into polymeric carriers 29 
that could be subsequently integrated into the CHA network during fabrication, an approach 30 
that has been successfully used in other collagen-based materials[17-20]. Ideally, these carriers 31 
would ensure the stability of the rhBMP-2 during the fabrication process and allow its 32 
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controlled delivery after implantation while maintaining the existing pore architecture, 1 
mechanical properties and proven biological activity of the underlying scaffold. In addition, 2 
the scaffold should act as a reservoir, protecting the therapeutics from degradation in vivo.   3 
With this in mind, the present work evaluated the potential of alginate and poly(lactic-co-4 
glycolic acid) (PLGA) microparticles as rhBMP-2 carriers and assessed the effect of the 5 
incorporation of different amounts of these polymers into the CHA scaffold. The rhBMP-2 6 
release kinetics from these constructs was determined and the bioactivity of the growth factor 7 
following both the polymeric encapsulation and inclusion into the CHA scaffold was tested in 8 
vitro on pre-osteoblastic cells. An optimal rhBMP-2 eluting microparticles/CHA scaffold 9 
composition was selected and its capability for enhancing bone tissue regeneration in vivo was 10 
determined by implanting it into a critical size calvarial defect of young male rats. 11 
4. Materials and Methods 12 
4.1. Materials 13 
Sodium alginate, calcium chloride, sodium chloride, polyvinyl alcohol (PVA), sodium 14 
hydroxide, sodium dodecyl sulphate (SDS) and PLGA (50:50, Mw 24,000-38,000) were 15 
purchased from Sigma Aldrich (Arklow, Ireland). Acetonitrile and dichloromethane (DCM) 16 
were purchased from Fisher Scientific (Ballycoolin, Ireland). Physiogel® was obtained as a 17 
kind gift from Braun Medical (Emmenbrucke, Switzerland). RhBMP-2 was purchased from 18 
R&D Systems Europe Ltd (UK). All chemicals were used as obtained, without further 19 
purification. 20 
4.2. Microparticle fabrication and characterization 21 
Alginate and PLGA were selected as the polymers for encapsulating rhBMP-2 as they have 22 
been widely used for drug delivery purposes; in addition, both are biodegradable, 23 
biocompatible and classified as generally regarded as safe (GRAS) by the FDA [21-23]. 24 
rhBMP-2 eluting alginate microparticles were manufactured by spray-drying. In this 25 
procedure, a polymeric feed solution is atomized and passed through a drying chamber, solvent 26 
from the droplets is evaporated and particulate powder is collected. In our study, rhBMP-2 was 27 
added to a sodium alginate solution (0.5% w/v) at a protein:polymer ratio of 1 µg/mg. This 28 
mixture was spray-dried using a Buchi Mini Spray-Dryer B290 with the following parameters: 29 
compressed air 5-8 bar, air flow rate 400-600 L/hr, inlet temperature 140 °C, aspirator 80% of 30 
maximum capacity and pump flow rate 15%. Alginate microparticles were crosslinked after 31 
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fabrication; the microparticles were suspended in acetonitrile, poured into 1.2% (w/v) calcium 1 
chloride while stirring for 10 mins after which they were vacuum filtered through a 0.45µm 2 
nylon membrane, washed twice with 10 mL distilled water and freeze-dried at -56 °C 3 
overnight. 4 
PLGA (50:50) microparticles were fabricated by a water-oil-water (W/O/W) emulsion method 5 
adapted from a previously described method[24]. Briefly, 0.5 mL of an aqueous solution of 16 6 
µg of growth factor was added to 125 µL of Physiogel® (80 mg/mL of succinylated gelatin) 7 
which has been reported to protect proteins from degradation (W1-Phase)[25]. PLGA (375 mg) 8 
was dissolved in 5 mL of dichloromethane (O-Phase). After mixing the W1-Phase with the O-9 
Phase, the mixture was ultrasonicated to obtain the primary W1/O emulsion. This W1/O 10 
emulsion was added dropwise while sonicating to 30 mL of an aqueous solution containing 1 11 
g of polyvinyl alcohol (PVA) and 1.13 g of NaCl. The resulting W1/O/W2 emulsion was 12 
dispersed in 70 mL of the same aqueous solution. This emulsion was stirred for 4 h at room 13 
temperature and the resulting microparticles were collected by centrifugation (5000 rpm, 10 14 
mins). The particles were washed three times with 1.13% (w/v) NaCl and freeze-dried at -56 15 
°C overnight. Blank, non-rhBMP-2 loaded alginate and PLGA microparticles were fabricated 16 
by adding distilled water instead of growth factor solutions during the respective procedures.  17 
The encapsulation efficiency of both processes was determined by digesting the microparticles 18 
and analyzing the concentration of rhBMP-2 in the medium. With this aim, 5 mg of alginate 19 
microparticles were dissolved in 10 mL of 0.1 M sodium citrate under magnetic stirring for 30 20 
mins and 20 mg of PLGA microparticles were added to 3 mL of a 0.1M NaOH, 5% w/v sodium 21 
dodecyl sulphate (SDS) solution in water at 37º C while shaking (50 rpm, 2 h). Digestion media 22 
were centrifuged (10,000 rpm, 2 mins) and the supernatant analysed for protein content using 23 
a rhBMP-2 ELISA kit (R&D Systems UK) according to the manufacturer’s instructions. The 24 
encapsulation efficiency was calculated using the following formula: 25 
EE(%)=(amount of rhBMP-2 in the microparticles/rhBMP-2 loaded)*100 26 
Microparticles were morphologically characterized with Scanning Electron Microscopy (SEM) 27 
using a Zeiss Supra Variable Pressure Field Emission SEM. For SEM observations, samples 28 
were mounted on copper studs with carbon glue and then sputtered with gold. 29 
To examine protein release profiles, 20 mg of rhBMP-2 microparticles dispersed in 2 mL of 30 
phosphate buffer solution (PBS) were placed in a waterbath at 37º C under agitation. At certain 31 
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timepoints, samples were centrifuged (10,000 rpm, 5 mins) and the release medium was 1 
removed and replaced by fresh PBS. The concentration of rhBMP-2 in the media was 2 
determined by ELISA as above. 3 
4.3. In vitro bioactivity assessment of rhBMP-2 encapsulated in the microparticles 4 
MC3T3-E1 murine pre-osteoblasts were used to study the effects of the released rhBMP-2 on 5 
osteoblast proliferation and differentiation in vitro since they exhibit similar properties as 6 
osteoprogenitor cell lines including high alkaline phosphatase (ALP) activity[26] and form 7 
calcified bone tissue[27]. Cells were cultured in α-MEM supplemented with 10% fetal bovine 8 
serum (FBS), 1% L-glutamine and 2% penicillin/streptomycin, the media was changed every 9 
3 days. Cells were trypsinised (trypsin–EDTA 0.25%), seeded on 6 well plates at a density of 10 
30,000 cells per well and cultured for 24 h in standard growth media followed by growth media 11 
supplemented with ascorbic acid 2-P 50 uM, dexamethasone 100 nM, β-glycerophosphate 10 12 
mM, FBS 10%, 100 U/mL penicillin, 100 ug/mL streptomycin under standard conditions (37 13 
°C, 5% CO2).  14 
In order to assess the bioactivity of the rhBMP-2 after the encapsulation process, 20 mg of 15 
alginate or PLGA microparticles were dispersed in 2 mL PBS and placed in a waterbath at 37º 16 
C under agitation. After 4 h, the samples were centrifuged (10,000 rpm, 5 mins), the release 17 
media collected and the concentration of rhBMP-2 determined by ELISA. Release medium 18 
was added to the osteogenic cell culture media at a final concentration of 50 ng/mL of rhBMP-19 
2 for each formulation (Alginate BMP-2 (50 ng/mL), PLGA BMP-2 (50 ng/mL)). To determine 20 
the effect of the dissolution product of blank microparticles on MC3T3 bioactivity, the same 21 
amount of media from blank microparticles that had been agitating for 4 h at 37 °C was added 22 
to another set of cells (blank alginate, blank PLGA). As a positive control, non-encapsulated 23 
rhBMP-2 at the same concentration (50 ng/mL) was added to the culture media (BMP-2 (50 24 
ng/mL)); this bioactive concentration is capable of inducing an osteogenic response from these 25 
cells[28]. Cells in the absence of rhBMP-2 or any additional media other than osteogenic 26 
differentiation media were used as negative control (cells alone). 27 
DNA was quantified from MC3T3-E1 cells cultured after 7 days in the presence of the different 28 
media. At the endpoint of the study cells were washed in PBS, lysed using cell lysis buffer 29 
according to the manufacturer’s instructions (SensoLyte pNPP Alkaline Phosphatase Assay 30 
Kit). Briefly, the cell suspension was centrifuged at 2500 X g for 10 mins at 4 ºC. The 31 
supernatant was analysed for dsDNA content using the PicoGreen assay (Quanti-iT TM 32 
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PicoGreen dsDNA Molecular Probes, OR, USA) according to the manufacturer’s instructions. 1 
To convert DNA content into cell number the DNA content per sample was related to the 2 
amount of DNA quantified per cell of a fixed number of cells. 3 
In order to assess the ability of rhBMP-2 released from the microparticles to enhance 4 
osteogenesis, alkaline phosphatase (ALP), an early marker for osteoblast differentiation, was 5 
quantified from MC3T3-E1 cells cultured in the presence of the different media[29]. With this 6 
purpose, after 7 days of culture, MC3T3-E1 cells were lysed as above and the supernatant was 7 
collected for quantification of ALP by a method utilizing p-nitrophenyl phosphate (pNPP), 8 
which is hydrolysed by ALP to produce a yellow product. The amount of coloured product is 9 
proportional to the amount of enzyme in the reaction. 10 
4.4. Scaffold fabrication and characterization 11 
The collagen-hydroxyapatite (CHA) scaffold is produced using a patented process developed 12 
within our laboratory[30]. Briefly, 1.8 g of micro-fibrillar bovine tendon collagen was added 13 
to 320 mL of 0.5 M acetic acid solution. This suspension was blended at 15,000 rpm for 90 14 
mins using an overhead blender in a reaction vessel which was kept at 4 °C using a circulation 15 
system to prevent heat denaturation of the collagen. Aliquots of 10 mL of a solution of 3.6 16 
grams of HA in 40 mL of 0.5 M acetic acid solution were added every 60 mins and the resulting 17 
slurry was blended for 60 additional mins. The slurry was degassed by vacuum to remove air 18 
bubbles that could produce uncontrolled porosity in the final scaffold.   19 
In order to assess the influence of the incorporation of different amounts of microparticles on 20 
the characteristics of the scaffolds, suspensions of 50, 100 or 200 mg of blank alginate or PLGA 21 
microparticles in 1 mL distilled water were mixed with 9 mL of CHA slurry, for final 22 
concentrations of 0.5, 1.1 and 2.2% w/v (weight of microparticles/volume of CHA slurry). The 23 
mixtures were lyophilized at -10 °C using a constant cooling freeze-drying protocol. In order 24 
to enhance the mechanical and enzymatic resistance of the scaffolds they were crosslinked 25 
under an ultra-violet (subtype C, 365 nm λ) lamp for 15 mins[31, 32]. Subsequently, the 26 
scaffolds were sterilised under UV light for 4 h (254 nm λ); this method was chosen for this 27 
study as it presented the lowest risk of material and/or rhBMP-2 damaging compared to other 28 
sterilization techniques (dehydrothermal treatment, gamma radiation, ethylene oxide or ethanol 29 
soaking).  The resulting scaffolds were denoted alginate-CHA and PLGA-CHA and compared 30 
with a blank scaffold fabricated with 1 mL of distilled water instead of the microparticle 31 
suspension. 32 
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The effect of microparticle incorporation on the mechanical properties of scaffolds was 1 
assessed and compared with blank CHA scaffolds. With this aim, wet compression testing was 2 
performed using a uniaxial tensile testing machine (Z050, Zwick/Roell, Ulm, Germany) fitted 3 
with a 5 N load cell. Disks of scaffolds (n=4) with diameters of 6 mm and a depth of 3 mm, 4 
obtained with a biopsy punch, were pre-hydrated prior to transfer to the testing rig. Uniaxial 5 
compression testing was performed up to a maximum strain of 10%. The modulus was 6 
calculated from the slope of the stress-strain curve over the range 2-5% strain.  Compressive 7 
testing results were analysed using an in-house designed Microsoft Excel macro.  8 
SEM characterization of the surface and the cross-section of the different composite scaffolds, 9 
carried out for assessing the distribution of the microparticles through the walls of the scaffolds, 10 
was performed using Zeiss Supra Variable Pressure Field Emission Scanning Electron 11 
Microscope. Samples were mounted on copper studs and were sputtered with gold prior to 12 
observation. In order to examine the effects of the inclusion of the microparticles on the porous 13 
structure of the scaffolds, they were embedded in JB-4-glycolmethacrylate® (Polysciences, 14 
Inc, UK) using a previously established method and then sectioned into 10 µm slices using a 15 
microtome[33]. Scaffold sections were mounted on glass slides and stained with Toludine blue. 16 
Digital images were captured at 10x magnification using a microscope (Eclipse 90i, Nikon, 17 
Japan) and a digital camera (DS Ri1, Nikon, Japan). To examine pore diameters the images 18 
were evaluated using MATLAB® pore topology analyser software, where original images 19 
were transformed into binary images[34]. The pore size was defined as the diameter of a circle 20 
with a cross-sectional area equivalent to that of the best fit ellipse generated by the software (at 21 
least 50 pores per section were considered for each analysis).  22 
The porosity of the scaffolds with and without microparticles was also calculated using the 23 
following equation: 24 
% porosity = 100 x [1 – (ρ actual / ρ theoretical)] 25 
The actual density (ρ actual) of the scaffolds was calculated by dividing the actual mass of the 26 
scaffolds to calculated volume of the scaffolds. The theoretical density (ρ theoretical) values 27 
were taken from the literature. Based on the results detailed in the next section, scaffolds with 28 
0.5% alginate and 2.2% (w/v) PLGA microparticles were deemed optimal and rhBMP-2 29 
eluting scaffolds were prepared with those compositions. 30 
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To examine protein release profiles, scaffolds (6 mm diameter) were placed in 2 mL of PBS, 1 
ensuring sink conditions, in a shaking water bath at 37º C. At given timepoints, release media 2 
were removed, replaced by fresh PBS and the protein concentration was determined by ELISA 3 
as outlined above. 4 
4.5. In vitro bioactivity assessment of rhBMP-2 delivered from scaffolds 5 
In order to analyse osteogenesis of the rhBMP-2 eluting scaffolds, MC3T3-E1 cells were 6 
cultured as detailed above. In a 24 well-plate, 6 mm diameter scaffolds were seeded drop-wise 7 
with 25 µL of a cell suspension and then placed in an incubator (37 °C, 5% CO2) for 15 mins, 8 
the discs were then turned over and another 25 µL of the cell suspension was added drop-wise 9 
for a total of 50,000 cells per scaffold. After 15 mins of incubation, 1 mL of media was added 10 
to each well and the scaffolds returned to the incubator. At day 3 and day 7, constructs were 11 
rinsed twice in PBS, flash frozen in liquid nitrogen and stored at -80 °C until analysis. To 12 
analyse the influence of rhBMP-2 eluting scaffolds on cell proliferation, DNA was quantified 13 
after 3 and 7 days of culture. At those timepoints, the cell seeded scaffolds were homogenised 14 
in lysis buffer using a rotor-stator homogeniser (Omni International, Germany), the 15 
cell/scaffold suspension was centrifuged (2500 X g, 10 mins, 4º C) and the supernatant was 16 
collected and used for DNA analysis as described above.  ALP was quantified from MC3T3 17 
cells cultured in direct contact with scaffolds after 7 days. Scaffolds were homogenised in lysis 18 
buffer and assayed according to the manufacturer protocol (SensoLyte pNPP Alkaline 19 
Phosphatase Assay Kit) as described previously. 20 
4.6. In vivo assessment of rhBMP-2 releasing scaffolds to enhance bone repair 21 
In order to assess the ability of BMP-2 eluting PLGA-CHA scaffolds to promote bone 22 
regeneration, scaffolds (n=8 per group) were implanted in 7 mm critical-sized calvarial defects 23 
[35] using adult male Wistar rats (mean weight 375 g) (Harlan, UK). For comparative purposes, 24 
a second group received blank non-eluting CHA scaffolds, while a third empty defect group 25 
received no scaffold, serving as a negative control. An animal license was granted by the Irish 26 
Government Department of Health (Ref. B100/4416) for carrying out this in vivo study 27 
conducted in accordance with protocols approved by the Research Ethics Committee of the 28 
Royal College of Surgeons in Ireland (REC Approval No. 662). 29 
The generation of a 7-mm-diameter critical-size calvarial defect, the implantation of the 30 
composite materials in the defect site, the procedures for induction of anaesthesia and the 31 
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procedures for postoperative animal care were performed using methods established in the 1 
Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland 2 
(RCSI)[36-38]. A trephine burr drill was used to create a 7 mm circular transosseous defect in 3 
the left parietal bone of the rat calvarium. The dura was identified to confirm that a transosseous 4 
defect had been created. Scaffolds were implanted into the defect, after which the periosteal 5 
and superficial connective tissue was closed in layers with 3-0 absorbable monofilament 6 
sutures (Monocryl™) and finally a topical skin adhesive (n-butyl cyanoacrylate) was 7 
applied. Post-operatively, rats were given a subcutaneous injection of the reversal agent 8 
atipemazole 1.2 mg/kg and placed in an incubator at 27º C until fully recovered. Animals were 9 
housed (2 per cage) in the Biomedical Research Facility at the RCSI with ad libitum access to 10 
water, food and environmental enrichment.  At 8 weeks post-implantation, the animals were 11 
euthanized by CO2 asphyxiation and cervical dislocation. A 20 mm x 20 mm segment of 12 
calvarium containing the defect was resected using a dental saw and the explants retrieved were 13 
stored in 10% neutral buffered formalin for 4 days and then transferred to PBS prior to 14 
decalcification. 15 
Explants were decalcified for a period of 5 weeks by immersing them in a solution of 16 
ethylenediaminetetraacetic acid (EDTA) 14% (w/v) at pH 7.4 with renewal of the solution 3-4 17 
times per week. Following decalcification, specimens were dehydrated in a graded series of 18 
ethanol solutions using an automated tissue processor, bisected and embedded in single paraffin 19 
wax blocks. 7 µm sections were cut from each sample using a rotary microtome and sections 20 
were mounted on L-polysine coated glass slides. Qualitative and quantitative histological 21 
examinations were performed on explants in order to assess the levels of bone formation in the 22 
defect site. Each section was stained with Haematoxylin and Eosin (H&E). Haematoxylin 23 
stains cell nuclei purple, eosin stains extracellular matrix pink and bone appears dark pink/red. 24 
Images of each specimen were acquired and digitized using transmitted light and 25 
epifluorescence microscopic visualisation (Nikon Microscope Eclipse 90i with Nis Elements 26 
software v3.06, Nikon Instruments Europe, The Netherlands). Quantitative analysis was 27 
performed on n=4 sections from each specimen. Histomorphometrical analysis (blind) was 28 
carried out in order to quantify the healing response from the H&E-stained samples. The defect 29 
margin was identified and any new bone was quantified by measuring the area of bone 30 
nucleation sites (BNS) in each section and calculating the mean total area of these sites per 31 
group. The area of new bone formation was calculated using Nis Elements software v3.06 32 
(Nikon Instruments Europe B.V, The Netherlands).  33 
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4.7. Statistical analysis 1 
The data are represented as means ± standard error of the mean (SEM). Statistics were carried 2 
out using GraphPad Prism software using a general linear model ANOVA with Bonferroni post 3 
hoc analysis. All in vitro experiments were performed with a sample size of 3 per treatment 4 
group and in vivo analysis was performed with a sample size of 8 per treatment group. 5 
Statistical significance was taken at p≤0.05 unless otherwise stated. 6 
 7 
5. Results 8 
SEM images, displayed in Figure 1, show that the spraydrying and double emulsion processes, 9 
used for the fabrication of alginate and PLGA carriers respectively, yield microparticles with 10 
a size within the 1-10 µm range, results that were corroborated by laser diffraction analyses 11 
(see supporting information). The morphology of the materials is very different depending on 12 
the fabrication procedure used; alginate microparticles are irregular in shape with a smooth 13 
surface while PLGA microparticles are spherical and porous. These features have been 14 
previously described for materials fabricated using similar procedures[39, 40].  15 
 16 
Figure 1. SEM micrographs of rhBMP-2 eluting alginate and PLGA microparticles showing 17 
particles within the 1-10 µm range.  18 
The encapsulation efficiency of rhBMP-2 for the processes, determined from digested 19 
microparticles, was 45% for the spraydried alginate microparticles and 83% for the PLGA 20 
microparticles fabricated by double emulsion technique. Figure 2 shows the release profile of 21 
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the encapsulated protein from these microparticles. The delivery of rhBMP-2 from alginate 1 
microparticles was characterised by an initial quick release for 7 days followed by a slower, 2 
sustained release for another 7 days. In contrast, the amount of rhBMP-2 delivered from PLGA 3 
microparticles was significantly lower than alginate. After an initial burst on the first day, the 4 
growth factor was released in a sustained manner for 14 days. After the initial burst, the delivery 5 
kinetics of rhBMP-2 from the polymers followed the Higuchi kinetics model of controlled 6 
release (see supporting information). At the end of the release study, alginate and PLGA 7 
microparticles had released 46% and 12% of their content respectively.  8 
 9 
Figure 2. rhBMP-2 release from the microparticles, showing different profiles for each 10 
polymer. 11 
Having determined the release kinetics of rhBMP-2 from the microparticles, the next step was 12 
to examine if the encapsulation process had affected the bioactivity of the growth factor. With 13 
this aim in mind, the bioactivity of MC3T3-E1 cells cultured with rhBMP-2 released from the 14 
microparticles and with the same concentration of non-encapsulated rhBMP-2 was assessed 15 
and compared. The results of this study are depicted in Figure 3. As shown in Figure 3, the 16 
effect of the eluted rhBMP-2 after 7 days of culture on cell number was not significantly 17 
different from that of non-encapsulated growth factor. However, although non-significant, 18 
there was a clear decrease in cell number when osteoblasts were seeded with medium where 19 
blank alginate microparticles had been suspended for 4 h compared to the cells alone control. 20 
The expression of ALP by cells cultured for 7 days with media from the different groups studied 21 
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is displayed in Figure 2. While ALP expression in cells cultured with rhBMP-2 released from 1 
both alginate and PLGA microparticles was significantly lower than the concentration in media 2 
where non-encapsulated rhBMP-2 was used, it was significantly higher than that of cells 3 
cultured without rhBMP-2, confirming that the eluted rhBMP-2 had retained its bioactivity 4 
after the encapsulation process. Interestingly, when the growth factor was released from PLGA 5 
microparticles, it had a significantly higher effect on ALP production by the cells compared to 6 
rhBMP-2 delivered by alginate microparticles. Media from blank PLGA and alginate 7 
microparticles had no effect on ALP levels in this study when compared to the control. 8 
 9 
Figure 3. MC3T3 E-1 cell number (A) and ALP concentration (B) in cell culture medium 10 
after 7 days of culture without rhBMP-2 and with rhBMP-2 released from the microparticles 11 
compared to negative (cells alone) and positive controls (non-encapsulated BMP-2). rhBMP-12 
2 released from the microparticles had a pro-osteogenic effect, as demonstrated by the 13 
enhanced ALP activity. *** denotes p<0.05 14 
14 
 
Once it was confirmed that it was possible to encapsulate and release bioactive rhBMP-2 from 1 
alginate and PLGA microparticles with the procedures detailed above, we then studied the 2 
effects of incorporating these microparticles into a CHA scaffold during its fabrication process. 3 
With this aim in mind, three different concentrations of blank microparticles (0.5%, 1.1% and 4 
2.2% weight of microparticles/volume of CHA slurry) were tested. 5 
SEM characterization of these constructs displayed in Figure 4, shows that the microparticles 6 
are integrated within the walls of the scaffold. In a parallel study, fluorescently labelled 7 
microparticles were also incorporated into the CHA scaffolds and the constructs were 8 
characterized by fluorescent microscopy. Results from this study corroborate that the 9 
microparticles were homogeneously distributed within the CHA network (see video in 10 
supporting information).  11 
 12 
Figure 4. SEM micrographs of cross-sections of CHA scaffolds with different concentrations 13 
of PLGA and alginate microparticles. Images, taken at 5000x magnification, demonstrate the 14 
integration of the microparticles within the walls of the scaffold 15 
An increase in the microparticle concentration within the CHA matrix led to a decrease in the 16 
pore diameter of the scaffolds, as shown in Figure 5A. This effect was also obvious when cross-17 
sections of the scaffolds were observed by SEM at low magnification (see supporting 18 
information). Although the average pore diameter of scaffolds with 1.1% and 2.2% 19 
microparticles was significantly lower than CHA scaffolds, it was over 75 µm in all the studied 20 
materials. The incorporation of the microparticles also induced a concentration-dependent 21 
15 
 
reduction in the porosity of the scaffolds (Figure 5B). However, porosity values were over 96% 1 
for all the CHA-microparticles scaffolds well above that typically desired to promote cell 2 
infiltration and subsequent vascularisation in vivo.[36, 41, 42] The inclusion of the 3 
microparticles within the CHA structure did not have a negative effect on the mechanical 4 
properties of the scaffolds. Indeed, as shown in Figure 5C, the compressive modulus of 0.5% 5 
and 2.2% alginate-CHA scaffolds were significantly higher than the blank-CHA control.  6 
Based on these results, and in order to have a similar amount of rhBMP-2 released from the 7 
scaffolds, CHA scaffolds incorporating 0.5% alginate or 2.2% PLGA rhBMP-2 eluting 8 
microparticles were fabricated (for a final content of 1.5 µg and 6.6 µg rhBMP-2/6 mm 9 
diameter scaffold respectively) and their rhBMP-2 release profiles and in vitro bioactivity 10 
investigated. Figure 6A shows the release profiles of rhBMP-2 from the two different scaffolds. 11 
The growth factor delivery from the constructs follows a different trend to that observed for 12 
their corresponding microparticles alone, i.e., a high burst release followed by a sustained 13 
release for only 7 days for BMP-2 eluting alginate-CHA scaffold and a sustained release 14 
through the whole study for the BMP-2 eluting PLGA-CHA scaffold. In addition, while PLGA 15 
based constructs released a similar amount of rhBMP-2 to that delivered from the 16 
microparticles alone in 28 days (ca. 12%), BMP-2 eluting alginate-CHA scaffolds only 17 
released 15% of the encapsulated growth factor. Interestingly, the alginate-CHA GF release 18 
follows the same kinetics model as the microparticles alone after the initial burst (Higuchi 19 
model), however, the delivery of rhBMP-2 from PLGA-CHA fits with a zero-order release 20 
kinetics profile from the beginning of the study, demonstrating the sustained delivery of the 21 
protein with time (see supporting information). 22 
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 1 
Figure 5. Pore diameter (A), porosity (B) and compressive modulus (C) of CHA scaffolds 2 
incorporating different concentrations of alginate or PLGA microparticles. The inclusion of 3 
the microparticles does not negatively affect the mechanical and structural properties of the 4 
scaffolds for bone tissue purposes. *** denotes p<0.05 5 
The results of the bioactivity tests of these scaffolds are summarized in Figures 6B and 6C. 6 
When compared to the non-eluting CHA control, there is a significant increase in the number 7 
of cells after 3 and 7 days of culture in both rhBMP2-eluting and blank PLGA-CHA scaffolds. 8 
In addition, after 7 days of culture, ALP expression in cells cultured in both rhBMP-2 eluting 9 
17 
 
PLGA-CHA and alginate-CHA scaffolds is higher than in the rest of analysed groups. 1 
However, comparing between growth factor releasing scaffolds, ALP expression is 2 
significantly higher in cells cultured in rhBMP-2 eluting PLGA-CHA scaffolds compared to 3 
those on alginate-CHA scaffolds.  4 
 5 
Figure 6. (A) Cumulative release of rhBMP-2 from alginate and PLGA– CHA scaffolds, (B) 6 
MC3T3-E1 cells number after 3 and 7 days of culture in the scaffolds and (C) ALP 7 
concentration in the culture medium after 7 days of culture in the rhBMP-2 eluting scaffolds 8 
and the non-eluting negative control scaffolds (CHA control). rhBMP-2 eluting PLGA-CHA 9 
scaffolds elicit an enhanced pro-osteogenic effect on osteoblasts. *** denotes p<0.01, ** 10 
denotes p<0.02 and * denotes p<0.05 11 
18 
 
Taken together, these results confirm that the rhBMP-2 eluted from PLGA-CHA scaffolds 1 
induces a higher osteogenic response in osteoblasts compared to that delivered from alginate-2 
CHA scaffolds. Thus, the healing potential of these scaffolds was assessed in vivo. The results 3 
of this study, which was carried out by implanting the materials in a cranial critical defect in 4 
male Wistar rats for 8 weeks, are displayed in Figure 7. 5 
The histological images taken from sections of the explants of the defect site at the end of the 6 
in vivo study demonstrate different levels of healing among the tested groups.  Thin fibrotic 7 
tissue, with some bone at the defect edges can be observed in samples where the defect was 8 
left empty demonstrating the critical nature of the defect created. Defects treated with non-9 
eluting blank CHA control scaffolds show a thin bone formation at the defect edges and in the 10 
centre of the defect, with a good cell infiltration. Most encouragingly, rhBMP-2 eluting 11 
scaffolds induced the formation of areas of bone throughout the defect space and within the 12 
boundaries as evidenced by more intense staining indicative of bone nucleation sites. In these 13 
samples, some areas of extracellular matrix deposition could be observed. In addition, the 14 
scaffold was almost completely resorbed.  The quantitative histomorphometrical analysis of 15 
the area of new bone formed in all groups (Figure 7B) supported these observations revealing 16 
significantly higher levels of new bone formation in animals treated with the rhBMP-2 eluting 17 
PLGA-CHA scaffold after 8 weeks compared to the empty defect (**P<0.001) and CHA 18 
control (*P<0.01). 19 
 20 
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Figure 7. (A) Representative images of sections of explants from 7 mm calvarial defects in 1 
Wistar rats left empty or treated with CHA scaffolds or rhBMP-2 eluting PLGA-CHA 2 
scaffolds during 8 weeks and quantification of new area of bone. Qualitatively and (B) 3 
quantitatively, enhanced bone healing is observed in defects where the growth factor eluting 4 
scaffold was implanted. ** denotes p<0.01 and * denotes p<0.05. 5 
6. Discussion 6 
The aim of the present study was to assess if rhBMP-2 eluting alginate and PLGA 7 
microparticles could be incorporated into CHA scaffolds as a means to control the release of 8 
the growth factor resulting in a therapeutic with enhanced capacity for bone repair. With this 9 
in mind, the effect of incorporating different amounts of these microparticles on the properties 10 
of the scaffolds was studied and the bioactivity of the growth factor in vitro post-incorporation 11 
into the scaffolds was analyzed and shown to be retained. The extensive characterization 12 
carried out in this work allowed for the design of a rhBMP-2 eluting PLGA microparticle-CHA 13 
scaffold composite with optimal structural characteristics for bone tissue regeneration. The 14 
regenerative capability of this controlled-delivery scaffold was tested in vivo, confirming its 15 
superior bone healing properties. 16 
The processes used for microparticle fabrication, spray-drying for alginate and double 17 
emulsion for PLGA, yielded microparticles with the expected micrometric size. The loading of 18 
the growth factor into the microparticles was achieved with high encapsulation efficiencies. 19 
This is an important feature in the system as it minimises the high cost of rhBMP-2. However, 20 
only a fraction of the encapsulated protein was delivered during the in vitro release studies. 21 
This might suggest that the protein was degraded during the study in the release medium, or, 22 
in the case of PLGA microparticles, rhBMP-2 was likely being retained by the succinylated 23 
gelatine which was used for increasing the efficiency of the growth factor loading process. 24 
Similar results have been obtained in previous studies where this additive has shown to delay 25 
the delivery of therapeutic proteins from PLGA microparticles [25]. Either way, the amount of 26 
growth factor released from the microparticles was considerably higher than the concentration 27 
range considered optimal for achieving a pro-osteogenic effect[28]. In addition, rhBMP-2 28 
encapsulated in the microparticles induced a pro-osteogenic response in preosteoblasts. The 29 
fact that the eluted growth factor did not elicit a pro-osteogenic effect comparable to that of 30 
non-encapsulated rhBMP-2 directly added to the cells suggests degradation of the protein 31 
during the encapsulation process, probably due to thermal (spray-drying) and mechanical 32 
20 
 
(double emulsion) stresses. One limitation of the present study was that the conformational 1 
integrity of rhBMP-2 post-encapsulation, prior to the bioactivity tests, was not assessed. 2 
However, more importantly from a therapeutic perspective, despite this, released growth 3 
factors led to a significant increase in ALP activity by the osteoblasts, which is indicative of an 4 
enhancement of cell differentiation towards a pro-osteogenic lineage. Interestingly, it was 5 
noted that ALP activity in cells grown with rhBMP-2 eluted from PLGA microparticles was 6 
significantly higher than that of cells cultured in the presence of growth factor released from 7 
the alginate microparticles. This result possibly suggests that the high temperatures from the 8 
spray-drying process may be degrading BMP-2.  A reduction in cell number was reported when 9 
osteoblasts were seeded with the dissolution products of ionically crosslinked calcium alginate 10 
microparticles, which may be attributed to the release of calcium ions into the surrounding 11 
media as a result of exchange with cations and protons from the medium[43]. Thus, the higher 12 
ionic content of the medium, as well as the changes of pH resulting from the dissolution process 13 
could be affecting cell numbers. 14 
Once it was determined that it was possible to load bioactive rhBMP-2 into these polymeric 15 
carriers, a series of CHA scaffolds incorporating different amounts of PLGA and alginate 16 
microparticles were fabricated with the aim of determining the effect of the inclusion of the 17 
carriers on the properties of the materials. Specifically, CHA scaffolds with 0.5%, 1.1% and 18 
2.2% (weight of microparticles/volume of slurry) were fabricated and compared to blank CHA 19 
scaffolds. The microparticles were incorporated into the scaffolds in an intermediate 20 
fabrication step by mixing them with the CHA slurry, prior to the final freeze-drying step. The 21 
microscopic characterization of the scaffolds confirmed it is possible to integrate the 22 
microparticles homogenously through the walls of the CHA network. In addition, irrespective 23 
of the polymer or the concentration of the microparticles, the resulting materials have high 24 
porosity, over 96%, with pore diameters over 75 µm, characteristics that are essential for bone 25 
tissue growth [36, 41, 42]. A small decrease in the average pore size of the freeze-dried 26 
materials was observed with increasing microparticle content.  This result may be attributed to 27 
the microparticles acting as additional nucleation sites for ice crystal formation during 28 
lyophilisation from which pores are formed resulting in smaller, more compact porous 29 
architecture. The incorporation of PLGA microparticles did not negatively affect the scaffold 30 
mechanical properties when compared to microparticle-free scaffolds. Interestingly, an 31 
increase in compressive modulus was actually seen in the alginate -CHA scaffolds with 32 
increasing concentrations of microparticles which may be attributed to the hydrophilic 33 
21 
 
microparticles reinforcing the scaffolds in a hydrophilic environment. Additionally, the porous 1 
architecture of the scaffold may have influenced this result since high MP concentrations 2 
reduced scaffold pore size resulting in a denser and tightly packed material. Based on these 3 
positive results, CHA scaffolds incorporating 0.5% rhBMP-2 eluting alginate or 2.2% rhBMP-4 
2 eluting PLGA microparticles were fabricated, in order to compare the protein release kinetics 5 
and the in vitro bioactivity of materials potentially releasing the same amount of growth factor.  6 
Several differences were observed when studying the release kinetics of rhBMP-2 from the 7 
scaffolds compared to their corresponding microparticles alone. For alginate, a higher 8 
concentration of the protein was released as a burst from the alginate-CHA constructs, and a 9 
much lower concentration was released by the end of the study (only 15% of the incorporated 10 
rhBMP-2). These two phenomena might be explained by the degradation of the outer layers of 11 
the microparticles when they were immersed in the acidic slurry before lyophilisation. The 12 
majority of the encapsulated rhBMP-2 is probably located in these outer layers of the 13 
microparticles; the aggregation of encapsulated molecules on the surface of spray-dried 14 
microparticles is an expected consequence of this fabrication process[44]. Thus, the partial 15 
degradation of the microparticles may have released part of the encapsulated growth factor to 16 
the CHA matrix, with a double effect. On the one hand, free, non-encapsulated rhBMP-2 might 17 
have diffused quicker to the surrounding medium leading to the burst delivery. On the other 18 
hand, the strong interaction of the rhBMP-2 with the hydroxyapatite component of the slurry 19 
may be hindering the delivery of a fraction of the protein, resulting in a much lower amount of 20 
protein released compared to the microparticles alone. These results suggest that alginate may 21 
be a useful carrier for other growth factors rather than BMP-2. In the case of rhBMP-2 eluting 22 
PLGA-CHA scaffolds, the release is more sustained for the duration of the study, which may 23 
be due to the integration of the microparticles within the scaffold; the CHA matrix is acting as 24 
an additional diffusive barrier for the delivery of the protein.   25 
Similarly rhBMP-2 eluting PLGA-CHA scaffolds induced a higher pro-osteogenic response in 26 
osteoblasts than rhBMP-2 eluting alginate-CHA scaffolds; rhBMP-2 released from PLGA-27 
CHA scaffolds was shown to significantly enhance the osteogenic differentiation of the cells. 28 
Interestingly, non-eluting blank PLGA-CHA scaffolds also induced an increase in cell numbers 29 
compared to CHA scaffolds, suggesting an anabolic effect of the PLGA-CHA composites. This 30 
phenomenon was previously observed in PLGA-collagen based hydrogel materials and can be 31 
attributed to the negatively charged carboxylate groups that result from PLGA degradation, 32 
attracting calcium and facilitating enhanced mineralisation [45]. Taken together, these results 33 
22 
 
demonstrate that it is possible to load and release, in a controlled fashion, a bioactive dosage 1 
of rhBMP-2 from CHA scaffolds by using PLGA as polymeric carrier of the protein. The 2 
potential of these materials for enhancing bone tissue regeneration was then tested in vivo.  3 
Qualitatively and quantitatively, the results from the in vivo study, carried out by implanting 4 
the scaffolds in a critical-sized bone defect, confirm that the rhBMP-2 eluting PLGA-CHA 5 
scaffolds enhance bone regeneration. Significantly greater bone regeneration was observed in 6 
this group when compared to empty defects and CHA control scaffolds, corroborating the 7 
bioactivity of the encapsulated rhBMP-2. This result also reinforces the beneficial role of 8 
PLGA as growth factor carrier, as it is protecting the protein from degradation in vivo, which 9 
otherwise would occur very rapidly[46]. Histological analysis demonstrated the 10 
osteoconductivity of these materials, as newly formed bone could be distinguished throughout 11 
the defect site. In addition the majority of the rhBMP-2 eluting PLGA-CHA scaffold has been 12 
infiltrated with cells at 8 weeks post-implantation. Furthermore, quantitative measurements of 13 
bone formation indicated significantly higher levels of new bone in the defects containing 14 
rhBMP-2 eluting PLGA-CHA scaffolds and to a lesser extent the non-rhBMP-2 eluting CHA 15 
scaffold. This study thus confirms the superior regenerative properties of these growth factor 16 
eluting scaffolds. According to previous studies, these results could be improved even further 17 
if these materials showed an initial burst of growth factor prior to the sustained release. It has 18 
been demonstrated that BMP-2 releasing scaffolds that display initial burst release followed by 19 
a sustained release of BMP-2 have been shown to promote more significantly enhanced bone 20 
regeneration in some studies compared to a sustained release alone [47]. This can be attributed 21 
to the burst release of BMP-2 promoting the recruitment of osteoprogenitors into the matrix. 22 
In this sense, a CHA scaffold with both alginate and PLGA growth factor carriers could be an 23 
ideal platform for obtaining such release profile.  24 
The present work demonstrates that, with the procedures detailed above, it is possible to 25 
fabricate growth-factor eluting microparticles and incorporate them into a collagen-based 26 
scaffold fabricated by a freeze-drying process for the sustained and controlled delivery of 27 
rhBMP-2, leading to materials with superior regenerative capabilities. This study has focused 28 
on a growth factor/scaffold composition and architecture optimized for bone tissue 29 
engineering. However, the potential of the platform described in the present work is enormous. 30 
By tuning the therapeutic molecule and the chemical nature of the matrix, similar systems can 31 
be developed for enhancing the healing of very diverse tissues such as cartilage, cornea or 32 
23 
 
peripheral nerves, which are also regenerated using freeze-dried collagen based scaffolds[48-1 
50]. 2 
7. Conclusions 3 
The development of collagen-hydroxyapatite scaffolds incorporating PLGA and alginate 4 
microparticles for the sustained and localized delivery of rhBMP-2 was investigated. The 5 
inclusion of high amounts of both microparticles had a minimal effect on the structural and 6 
mechanical properties of the scaffolds. Bioactive rhBMP-2 was successfully released from both 7 
sets of microparticles within the scaffolds but PLGA-collagen hydroxyapatite scaffolds showed 8 
a higher pro-osteogenic effect in vitro than the growth factor delivered from alginate-collagen 9 
hydroxyapatite scaffolds. The regenerative effect was demonstrated as PLGA-collagen 10 
hydroxyapatite scaffolds led to significantly higher bone regeneration after 8 weeks of 11 
implantation in a critical-sized bone defect. These platforms have the potential to be used for 12 
delivering therapeutics to various tissues in addition to bone by adjusting the composition of 13 
the scaffold and the growth factor released. 14 
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Figure S1. Alginate and PLGA microparticle size as demonstrated by laser diffraction 1 
analyses. 2 
 3 
Figure S2. Release kinetics determination for the different rhBMP-2 eluting microparticles 4 
and scaffold composites 5 
 6 
Figure S3. SEM micrographs of cross-sections of CHA scaffolds with different 7 
concentrations of PLGA and alginate microparticles. Images taken at 800x magnification.  8 
